Fairtree Asset Management Pty Ltd Makes New $2.38 Million Investment in Edwards Lifesciences Corporation $EW

Fairtree Asset Management Pty Ltd purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 26,339 shares of the medical research company’s stock, valued at approximately $2,383,000. Edwards Lifesciences accounts for approximately 0.9% of Fairtree Asset Management Pty Ltd’s investment portfolio, making the stock its 26th largest holding.

A number of other hedge funds have also modified their holdings of the company. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences in the first quarter worth $25,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth $27,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $90.02 on Friday. The firm has a market cap of $51.83 billion, a price-to-earnings ratio of 51.74, a P/E/G ratio of 2.32 and a beta of 0.85. The firm has a fifty day moving average price of $89.12 and a 200 day moving average price of $84.63. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EW shares. Robert W. Baird increased their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Barclays reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.